IAVI HIV Vaccine

Study at a Glance

Estimated Time Commitment

To be discussed

Eligibility

Eligible population: Healthy adults 18-50

Diagnosis Required

Healthy Adult 18-50

Diseases Being Studied

HIV-1
Location: San Antonio, TX

Sponsor: IAVI

Coordinating Center/CRO: IAVI

Primary Objective: Phase 1 study to evaluate safety and immunogenicity of mRNA vaccine in HIV-1 Uninfected adults

Study drugs mRNA-1644 and mRNA-1644v2-Core

Sample size: 56, up to 15 locally

Start up status: Dry run completed, Now on protocol V4, has been approved, a couple more SOPs and drug shipment and we will be ready to enroll. ImageBloomhas been doing prescreening and there are potential subjects in the wings ready for final screening once we get greenlight.

Meet Your Clinical Research Team

Contact us

Principal Investigator: Local PI: Jan Patterson, M.D., M.S., Philip Ponce, M.D., John Daniels D.O., Alia Nazarullah M.D., and Rajeev Suri, MD, MBA, FACR, FSIR

For more information please contact Dr. Thomas Patterson